Clinical Trial

Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and concurrent or delayed radiotherapy in patients with advanced HER2-negative breast cancer with brain metastasis
Trial Details
NCT Number NCT06839560
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Brain Metastasis From Advanced HER2-negative Breast Cancer
Enrollment 102 participants
Start Date 2025-03-01
Primary Completion 2028-09-10 (estimated)
Study Completion 2028-09-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-10